Gordian Bio Releases Preprint Demonstrating Scalable In Vivo Mosaic Screening Platform to Establish Causal Disease Biology
Gordian Biotechnology, a biotechnology company focused on discovering and validating therapeutic targets through causal biology, today announced the release of a new preprint, titled: “A Multispecies, Modality-Agnostic Scalable In Vivo Mosaic Screening Platform for Therapeutic Target Discovery,” which describes a scalable in vivo perturb-seq platform that enables pooled genetic screening directly in living organisms across multiple tissues and disease contexts.
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity
Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for chronic diseases, today announced a non-exclusive research collaboration with Pfizer to apply Gordian’s proprietary in vivo mosaic screening platform to accelerate the discovery of therapeutic targets for obesity.
